Cusick J D, Dotan J, Jaecks R D, Boyle W T
Department of Surgery, San Bernardino County Medical Center, California.
Surg Gynecol Obstet. 1990 May;170(5):407-10.
The ideal diagnostic method for carcinoma of the breast remains controversial. In recent years, major centers with a large volume of patients and with experienced cytopathologists have popularized fine-needle aspiration cytology (FNAC). We have used the Tru-Cut (Travenol Lab) needle biopsy (TCNB) as the primary method of diagnosing carcinoma of the breast in patients with suggestive masses. During the years 1980 to 1988, 96 patients underwent TCNB. Of the 90 patients with subsequently proved carcinoma, TCNB confirmed the diagnosis in 87 per cent and yielded false-negative and inconclusive diagnoses in 11 and 2 per cent, respectively. No false-positive diagnoses were seen. Any negative result in a suggestive mass was followed by an open biopsy. The sensitivity rate herein was 89 per cent, the specificity rate, 100 per cent, and the over-all accuracy rate, 88 per cent. As a diagnostic tool, TCNB has been highly accurate, safe and free from false-positive findings. Unlike FNAC, TCNB requires no special skills on the part of the clinician or pathologist, thus making it suitable for community practitioners.
乳腺癌的理想诊断方法仍存在争议。近年来，拥有大量患者且配备经验丰富细胞病理学家的主要中心已推广细针穿刺细胞学检查（FNAC）。我们将Tru-Cut（Travenol实验室）针吸活检（TCNB）作为对有可疑肿块患者进行乳腺癌诊断的主要方法。在1980年至1988年期间，96例患者接受了TCNB。在随后被证实患有癌症的90例患者中，TCNB确诊率为87%，假阴性和诊断不明确率分别为11%和2%。未出现假阳性诊断。对任何可疑肿块的阴性结果均随后进行开放活检。此处的灵敏度为89%，特异度为100%，总体准确率为88%。作为一种诊断工具，TCNB高度准确、安全且无假阳性结果。与FNAC不同，TCNB对临床医生或病理学家而言不需要特殊技能，因此适合社区医生使用。
